CTKB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cytek Biosciences Inc (CTKB) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the company has shown revenue growth, its declining net income, EPS, and gross margin raise concerns about profitability. Additionally, the technical indicators and trading sentiment do not provide a compelling entry point. It is better to hold off on investing in this stock until there are clearer signs of financial recovery and stronger positive catalysts.
The MACD is positive and expanding, suggesting a slight bullish momentum, but the RSI is neutral at 49.465, indicating no clear trend. Moving averages are converging, and the stock is trading near its pivot level of $4.288. There is no strong technical signal suggesting a breakout or significant upward movement.
Record Q4 2025 revenue of $62.1 million, an 8% YoY increase, driven by strong performance in Asia-Pacific and Europe. Engagement at the 44th Annual J.P. Morgan Healthcare Conference may lead to future financing and partnerships.
Net income dropped by -100.46% YoY, and gross margin declined by -9.62% YoY. The stock has a 60% chance of declining in the next day, week, and month based on historical patterns.
In Q4 2025, revenue increased by 8.12% YoY to $62.1 million. However, net income dropped to -$44,076, a decline of -100.46% YoY. EPS fell to $0, down -100.00% YoY, and gross margin decreased to 52.92%, down -9.62% YoY.
TD Cowen raised the price target from $4 to $5 and maintained a Buy rating, citing optimism about multi-year growth frameworks. However, the stock's recovery is contingent on 2026 guidance updates and sector positioning.
